Mark J. Ratain to Lymphoproliferative Disorders
This is a "connection" page, showing publications Mark J. Ratain has written about Lymphoproliferative Disorders.
Connection Strength
0.167
-
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol. 1996 Jan; 14(1):188-95.
Score: 0.132
-
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
Score: 0.030
-
Evaluation of Leu-M5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique. Am J Clin Pathol. 1988 Sep; 90(3):250-6.
Score: 0.005